PDCD1 and non-small cell lung carcinoma: In recent years, immune checkpoint blocking using anti-CTLA-4 and anti-PD-1 antibodies has been successfully applied to tackle some types of advanced tumors, including non-small cell lung cancer (NSCLC), melanoma, bladder cancer, and Hodgkin’s lymphoma.